226 related articles for article (PubMed ID: 12397858)
1. Emerging role of drug interaction studies in drug development: the good, the bad, and the unknown.
Alfaro CL
Psychopharmacol Bull; 2001; 35(4):80-93. PubMed ID: 12397858
[TBL] [Abstract][Full Text] [Related]
2. New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process.
Huang SM; Strong JM; Zhang L; Reynolds KS; Nallani S; Temple R; Abraham S; Habet SA; Baweja RK; Burckart GJ; Chung S; Colangelo P; Frucht D; Green MD; Hepp P; Karnaukhova E; Ko HS; Lee JI; Marroum PJ; Norden JM; Qiu W; Rahman A; Sobel S; Stifano T; Thummel K; Wei XX; Yasuda S; Zheng JH; Zhao H; Lesko LJ
J Clin Pharmacol; 2008 Jun; 48(6):662-70. PubMed ID: 18378963
[TBL] [Abstract][Full Text] [Related]
3. Assessing the efficiency of mixed effects modelling in quantifying metabolism based drug-drug interactions: using in vitro data as an aid to assess study power.
Johnson TN; Kerbusch T; Jones B; Tucker GT; Rostami-Hodjegan A; Milligan PA
Pharm Stat; 2009; 8(3):186-202. PubMed ID: 19291743
[TBL] [Abstract][Full Text] [Related]
4. In vitro metabolic interaction studies: experience of the Food and Drug Administration.
Yuan R; Parmelee T; Balian JD; Uppoor RS; Ajayi F; Burnett A; Lesko LJ; Marroum P
Clin Pharmacol Ther; 1999 Jul; 66(1):9-15. PubMed ID: 10430104
[TBL] [Abstract][Full Text] [Related]
5. Prediction of drug metabolism and interactions on the basis of in vitro investigations.
Pelkonen O; Turpeinen M; Uusitalo J; Rautio A; Raunio H
Basic Clin Pharmacol Toxicol; 2005 Mar; 96(3):167-75. PubMed ID: 15733211
[TBL] [Abstract][Full Text] [Related]
6. The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective.
Bjornsson TD; Callaghan JT; Einolf HJ; Fischer V; Gan L; Grimm S; Kao J; King SP; Miwa G; Ni L; Kumar G; McLeod J; Obach SR; Roberts S; Roe A; Shah A; Snikeris F; Sullivan JT; Tweedie D; Vega JM; Walsh J; Wrighton SA;
J Clin Pharmacol; 2003 May; 43(5):443-69. PubMed ID: 12751267
[TBL] [Abstract][Full Text] [Related]
7. The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective.
Bjornsson TD; Callaghan JT; Einolf HJ; Fischer V; Gan L; Grimm S; Kao J; King SP; Miwa G; Ni L; Kumar G; McLeod J; Obach RS; Roberts S; Roe A; Shah A; Snikeris F; Sullivan JT; Tweedie D; Vega JM; Walsh J; Wrighton SA; ;
Drug Metab Dispos; 2003 Jul; 31(7):815-32. PubMed ID: 12814957
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic protein-drug interactions and implications for drug development.
Huang SM; Zhao H; Lee JI; Reynolds K; Zhang L; Temple R; Lesko LJ
Clin Pharmacol Ther; 2010 Apr; 87(4):497-503. PubMed ID: 20200513
[TBL] [Abstract][Full Text] [Related]
9. Impact of parallel pathways of drug elimination and multiple cytochrome P450 involvement on drug-drug interactions: CYP2D6 paradigm.
Ito K; Hallifax D; Obach RS; Houston JB
Drug Metab Dispos; 2005 Jun; 33(6):837-44. PubMed ID: 15897600
[TBL] [Abstract][Full Text] [Related]
10. Human hepatocytes: isolation, cryopreservation and applications in drug development.
Li AP
Chem Biol Interact; 2007 May; 168(1):16-29. PubMed ID: 17270162
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo induction of cytochrome p450: a survey of the current practices and recommendations: a pharmaceutical research and manufacturers of america perspective.
Chu V; Einolf HJ; Evers R; Kumar G; Moore D; Ripp S; Silva J; Sinha V; Sinz M; Skerjanec A
Drug Metab Dispos; 2009 Jul; 37(7):1339-54. PubMed ID: 19389860
[TBL] [Abstract][Full Text] [Related]
12. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
13. Induction of drug metabolizing enzymes: a survey of in vitro methodologies and interpretations used in the pharmaceutical industry--do they comply with FDA recommendations?
Hewitt NJ; de Kanter R; LeCluyse E
Chem Biol Interact; 2007 May; 168(1):51-65. PubMed ID: 17239835
[TBL] [Abstract][Full Text] [Related]
14. [Research in the field of clinical pharmacology in the USSR].
Lakin KM; Makarov VA; Novikova NV
Farmakol Toksikol; 1982; 45(3):5-12. PubMed ID: 7047211
[TBL] [Abstract][Full Text] [Related]
15. Prediction of CYP-mediated drug interactions in vivo using in vitro data.
Foti RS; Wahlstrom JL
IDrugs; 2008 Dec; 11(12):900-5. PubMed ID: 19051152
[TBL] [Abstract][Full Text] [Related]
16. Comparative studies on the cytochrome p450-associated metabolism and interaction potential of selegiline between human liver-derived in vitro systems.
Salonen JS; Nyman L; Boobis AR; Edwards RJ; Watts P; Lake BG; Price RJ; Renwick AB; Gómez-Lechón MJ; Castell JV; Ingelman-Sundberg M; Hidestrand M; Guillouzo A; Corcos L; Goldfarb PS; Lewis DF; Taavitsainen P; Pelkonen O
Drug Metab Dispos; 2003 Sep; 31(9):1093-102. PubMed ID: 12920164
[TBL] [Abstract][Full Text] [Related]
17. Mechanism-based inactivation of human cytochrome P450 enzymes: strategies for diagnosis and drug-drug interaction risk assessment.
Venkatakrishnan K; Obach RS; Rostami-Hodjegan A
Xenobiotica; 2007; 37(10-11):1225-56. PubMed ID: 17968744
[TBL] [Abstract][Full Text] [Related]
18. Drug interactions evaluation: an integrated part of risk assessment of therapeutics.
Zhang L; Reynolds KS; Zhao P; Huang SM
Toxicol Appl Pharmacol; 2010 Mar; 243(2):134-45. PubMed ID: 20045016
[TBL] [Abstract][Full Text] [Related]
19. Strategies to assess the drug interaction potential in translational medicine.
Persiani S; Larger P
Expert Opin Drug Metab Toxicol; 2006 Oct; 2(5):675-86. PubMed ID: 17014388
[TBL] [Abstract][Full Text] [Related]
20. The pivotal role of hepatocytes in drug discovery.
Soars MG; McGinnity DF; Grime K; Riley RJ
Chem Biol Interact; 2007 May; 168(1):2-15. PubMed ID: 17208208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
